MediciNova, Inc.
MNOVHealthcare|Biotechnology|US
$1.46
+0.01 (+0.69%)
DCF Value
$0.61
Tangible Book / Share
$0.46
Cash / Share
$0.52
Clinical Trials (21)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04057898 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | Amyotrophic Lateral Sclerosis | P2P3 | Active | 234 | RCT, Double-blind | MN-166, placebo |
| NCT05464784 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Diabetes Mellitus, Type 2, Hypertriglyceridemia | P2 | Active | 40 | RCT, Double-blind | MN-001, MN-001 placebo |
| NCT00838591 Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma | Asthma | P2 | Completed | 176 | RCT, Double-blind | MN-221, Placebo |
| NCT00679263 Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma | Asthma | P2 | Completed | 17 | RCT, Single-blind | MN-221, MN-221, Placebo |
| NCT02238626 Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 70 | RCT, Double-blind | Placebo (for MN-166), MN-166, riluzole |
| NCT00683449 Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma | Asthma, Status Asthmaticus | P2 | Terminated | 29 | RCT, Single-blind | Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3 |
| NCT00295854 Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | Interstitial Cystitis | P2 | Completed | 296 | RCT, Double-blind | MN-001 BID, MN-001, Placebo |
| NCT01740414 Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers | Opioid Abuse, Opioid Dependence | P2 | Completed | 28 | RCT, Double-blind | MN-166 (50 mg) First, Placebo First |
| NCT03782415 Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | Glioblastoma, Recurrent Glioblastoma | P1P2 | Completed | 64 | Open-label | MN-166, Temozolomide |
| NCT01982942 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | P2 | Completed | 255 | RCT, Double-blind | ibudilast, Placebo oral capsule |
| NCT03594435 Ibudilast for the Treatment of Alcohol Use Disorder | Alcohol Use Disorder | P2 | Completed | 102 | RCT, Double-blind | Ibudilast, Placebo oral capsule |
| NCT02503657 Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis, IPF | P2 | Completed | 15 | RCT, Double-blind | MN-001, Placebo |
| NCT04429555 Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS | Pneumonia, Viral | P2 | Completed | 34 | RCT, Double-blind | Ibudilast, Placebo |
| NCT02714036 A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P1P2 | Completed | 35 | Open-label | ibudilast, Ibudilast |
| NCT02681055 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects | Non-alcoholic Steatohepatitis, Hypertriglyceridemia | P2 | Completed | 19 | Open-label | MN-001 |
| NCT03533387 Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 28 | RCT, Open-label | MN-166 |
| NCT01013142 Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P1 | Completed | 48 | RCT, Double-blind | MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3) |
| NCT01551316 Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients | Chronic Obstructive Pulmonary Disease | P1 | Completed | 19 | RCT, Double-blind | MN-221, Placebo |
| NCT01217970 Safety Interaction Trial Ibudilast and Methamphetamine | Methamphetamine-dependence, Substance Abuse | P1 | Completed | 11 | RCT, Double-blind | Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet |
| NCT04054206 Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 12 | RCT, Open-label | MN-166 |
| NCT06743776 Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS | ALS | NO_LONGER_AVAILABLE | — | — | MN-166 |